Suggested remit: To appraise the clinical and cost effectiveness of encorafenib with binimetinib within its marketing authorisation for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer (NSCLC).
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6177

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6177 24 May 2024 - 24 June 2024

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
24 May 2024 In progress. Scoping commencing
03 July 2023 Please note that following on from an update received from the company, appraisal has been scheduled into the work programme. The appraisal is now anticipated to begin during mid-July 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-September 2024.
12 September 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual